Hints and tips:
Related Special Reports
...included Belgian pharmaceutical subsidiary Janssen and US drug group Merck....
...Janssen, the pharmaceuticals division of J&J, and Pfizer both started their phase 3 trials in September last year....
...“Multiple positive developments alongside a clear path set towards reopening warrant an upgrade,” they wrote in a research report....
...Extracts from his discussion with Alix Steel and Guy Johnson: AS: Were you aware of this risk when using the platform?...
...Both Johnson & Johnson and Novavax have said their vaccines were less effective against the strain in clinical trials conducted in South Africa....
...Ben Johnson, director of global ETFs and passive strategies research at Morningstar, agrees, pointing out that thematic ETFs tend to “appeal to investors’ appetite for narrative, belonging and the prospect...
...These companies spent $47bn on research and development over the 30 months, as well as issuing $14bn in new stock....
...The pandemic has compressed into months vaccine research and development that can take years....
...Mathai Mammen, global head of Janssen Research & Development at Johnson & Johnson, said the company looked forward to “discussing with public health officials a potential strategy for our Johnson & Johnson...
...Mathai Mammen, global head of Janssen Research & Development at Johnson & Johnson, said: “We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson Covid-19...
...J&J is preparing to test a new formulation that could be targeted at the 501.v2 variant, but Mathai Mammen, global head of research and development for Janssen, J&J’s pharmaceuticals division, said he was...
...In early January, the company announced it had an agreement with German pharmaceutical group Bayer to support the vaccine’s development....
...Development partnerships in this field include a recent licensing contract between Santen, a Japanese pharmaceutical company, and jCyte, a California-based biotech company, to develop and commercialise gene...
...It is now time to do the same for tech development: a proposal I call the “Technology 10”....
...Robert F Kennedy Jr, son of Robert F Kennedy and a prominent anti-vaccination campaigner....
...Mathai Mammen, global head of Janssen Research and Development, a subsidiary of Johnson & Johnson, said Spravato was a “unique and innovative medicine” that had the potential to offer “new hope” to the third...
...Since then other partnerships have been announced, including agreements with Janssen, a pharmaceutical arm of Johnson & Johnson, and AstraZeneca....
...But a more precise understanding of biology has led pharmaceutical companies to focus research and development efforts on treatments for rarer diseases, often aimed at small sub groups with a particular...
...“The Car-T technology is moving very quickly,” says Peter Lebowitz, global head of oncology at Janssen, the drugmaking unit of Johnson & Johnson....
...The 49-year-old is now commercial lead for haematology at Janssen, Johnson & Johnson’s pharmaceutical arm....
...Legend also piqued the interest of executives at Johnson & Johnson, the world’s largest healthcare company....
...We are speaking only days after Boris Johnson, then UK foreign secretary, flatly dismissed corporate concerns about Brexit with a coarse “f**k business”. What about that?...
...Ben Johnson, director of passive funds research at Morningstar, the data provider says: “State Street historically suffered from a lack of focus on the ETFs that make the core building blocks of investors...
...Ben Johnson, director of global ETF research at Morningstar, thinks BlackRock and Vanguard will continue to dominate the leader board....
...Johan Van Hoof, head of infectious diseases and vaccines at Janssen, part of the Johnson & Johnson pharmaceuticals group, says he also has cause for optimism....
International Edition